Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201137 | 0.89 | GRM5 (0.44) | TACR1KMT2AMEN1GRM5POLB | |
| SCHEMBL25090325 | 0.89 | GRM5 (0.44) | TACR1KMT2AMEN1GRM5POLB | |
| SCHEMBL29328059 | 0.80 | TACR1 (0.45) | TACR1KMT2AMEN1NPC1LIPG | |
| SCHEMBL29328327 | 0.79 | TACR1 (0.42) | TACR1KMT2AMEN1POLBNOTCH1 | |
| SCHEMBL30201121 | 0.77 | MEN1 (0.46) | TACR1KMT2AMEN1MC4RMAPT | |
| SCHEMBL25090446 | 0.77 | MEN1 (0.46) | TACR1KMT2AMEN1MC4RMAPT | |
| SCHEMBL25090209 | 0.77 | TACR1 (0.43) | TACR1KMT2AMEN1POLBNOTCH1 | |
| SCHEMBL25090352 | 0.77 | TACR1 (0.47) | TACR1KMT2AMEN1LIPGMAPT | |
| SCHEMBL25090079 | 0.77 | TACR1 (0.45) | TACR1KMT2AMEN1MAPT | |
| SCHEMBL30201079 | 0.77 | TACR1 (0.45) | TACR1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | TACR1 174/4885KMT2A 882/4885MEN1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.